The only pre-exposure prophylaxis approved for twice-a-year dosing, lenacapavir "could be the transformative PrEP option we’ve been waiting for," one expert said.
Killian Meara
Advertisement
Articles by Killian Meara
If the FDA approves the treatment, it will be the first-ever MDMA-assisted therapy and psychedelic-assisted therapy. The PDUFA date is set for August 11, 2024.
Moderna's investigational vaccine against RSV in adults showed mean efficacy of 83% against the infection and is the only mRNA technology-based RSV shot.
The finding implies the potential for virus transmission after initial recovery from the infection, according to study authors.
Advertisement
Latest Updated Articles
Moderna mRNA RSV Vaccine for Adults Returns Positive Phase 3 ResultsJanuary 8th 2024
First-Ever MDMA-Assisted Therapy for PTSD is Granted FDA Priority ReviewFebruary 13th 2024
Advertisement
Advertisement
Trending on Patient Care Online
1
FDA Issues Complete Response Letter for Cingulate ADHD Drug CTx-1301
2
FDA Approves Xocova as First Oral COVID-19 Postexposure Prophylaxis Option
3
Pediatric Influenza Vaccination Linked to Fewer Diagnoses in Claims Study
4
Transdermal Hormone Therapy for VMS and Cardiovascular Risk Management
5